Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

Jul. 20, 2022—In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

Read more